This article describes the development of a statewide program providing continuity of hepatitis C virus (HCV) treatment to prisoners upon release to the community. We discussed length of stay as a barrier to treatment with key collaborators; developed protocols, a referral process, and forms; mobilized staff; recruited heath-care facilities to accept referrals; and provided short-term access to HCV medications for inmates upon release. The Hepatitis C Continuity Program, including 70 prisons and 21 health-care facilities, is a resource for as many as 130 inmates eligible to start treatment annually. Health-care facilities provide fairly convenient access to 87.1% of releasees, and 100% offer integrated HCV-human immunodeficiency virus/acquired immunodeficiency syndrome care. As of March 2006, 24 inmates had been enrolled. The program was replicated in the New York City Rikers Island jail. The program is operational statewide, referrals sometimes require priority attention, and data collection and other details are still being addressed.
References
1.
BraithwaiteRLHammettTMMayberryRM. Prisons and AIDS: a public health challenge. San Francisco: Jossey-Bass Publishers; 1996.
2.
GlaserJBGreifingerRB. Correctional health care: a public health opportunity. Ann Intern Med1993; 118:139–45.
3.
HammettTM. Public health/corrections collaborations: prevention and treatment of HIV/AIDS, STDs, and TB. Research in brief. Washington, DC: U.S. Department of Justice, Office of Justice Programs, National Institute of Justice; July 1998 Report No. NCJ 169590.
4.
HammettTMHarmonMPRhodesW. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health2002; 92:1789–94.
5.
WeinbaumCMLyerlaRMargolisHS; Centers for Disease Control and Prevention (US). Prevention and control of infections with hepatitis viruses in correctional settings. MMWR Recomm Rep2003; 52(RR-1):1–36.
6.
WeinbaumCMSabinKMSantibanezSSHepatitisB, Hepatitis C, and HIV in correctional populations: a review of epidemiology and prevention. AIDS2005; 19(Suppl 3):S41–6.
7.
AllwrightSBradleyFLongJBarryJThorntonLParryJV. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. BMJ2000; 321:78–82.
8.
BoutwellAEAllenSARichJD. Opportunities to address the hepatitis C epidemic in the correctional setting. Clin Infect Dis2005; 40(Suppl 5):S367–72.
9.
FoxRKCurrieSLEvansJWrightTLToblerLPhelpsB. Hepatitis C virus infection among prisoners in the California state correctional system. Clin Infect Dis2005; 41:177–86.
10.
MacalinoGEVlahovDSanford-ColbySPatelSSabinKSalasC. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health2004; 94:1218–23.
11.
PradhanMMHorswellRJonesGRamseyJLCassidyW. Evaluation of The Federal Bureau of Prisons protocol for selection of which hepatitis C-infected inmates are considered for treatment. Dig Dis Sci2005; 50:714–8.
12.
TheodoreDDoughertyKASmithPZacksSGalankoJRussoM. Increasing liver-related mortality in incarcerated populations. Hepatology2003; 38:694A.
13.
Association of State and Territorial Health Officials (ASTHO). Hepatitis C in incarcerated populations: the next wave for correctional health initiatives. Washington, DC: 2001.
14.
CassidyWMGuidryDColtonCE. Hepatitis C in corrections: testing treatment and co-infection. Infectious Diseases in Corrections Report2005; 8:1–3.
15.
MacalinoGEDhawanDRichJD. A missed opportunity: hepatitis C screening of prisoners. Am J Public Health2005; 95:1739–40.
16.
National Institutes of Corrections (US). The health status of soon-to-be-released inmates: a report to Congress, Volume 1. Chicago, IL: NIC; 2002.
17.
ReindollarRW. Hepatitis C and the correctional population. Am J Med1999; 107(6B):100S–103S.
18.
FarleyJVasdevSFischerBHaydonERehmJFarleyTA. Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am J Public Health2005; 95:1737–9.
19.
ShawFEBeilensonW. Hepatitis C control in prisons remains an elusive goal. Hepatitis Control Report1999; 4:1–4.
20.
SylvestreDLLoftisJMHauserPGenserSCesariHBorekN. Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health2004; 81:719–34.
21.
BeckAJMaruschakLM. Hepatitis testing and treatment in state prisons. Bureau of Justice Statistics Special Report. Washington, DC: Department of Justice (US); 2004; Report No.: NCJ 199173.
22.
SpauldingAGreeneCDavidsonKSchneidermannMRichJ. Hepatitis C in state correctional facilities. Prev Med1999; 28:92–100.
23.
AllenSASpauldingACOseiAMTaylorLECabralAMRichJD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med2003; 138:187–90.
24.
SterlingRKHofmannCMLuketicVASanyalAJContosMJMillsAS. Treatment of chronic hepatitis C in the Virginia Department of Corrections: can compliance overcome racial differences to response?Am J Gastroenterol2004; 99:866–72.
25.
BennettWGPaukerSGDavisGLWongJB. Modeling therapeutic benefit in the midst of uncertainty: therapy for hepatitis C. Dig Dis Sci1996; 41(12 Suppl):56S–62S.
26.
DusheikoGMRobertaJA. Treatment of chronic type B and C hepatitis with interferon alpha: an economic appraisal. Hepatology1995; 22:1863–73.
ShiellABriggsAFarrellGC. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust1994; 160:268–72.
29.
HarrisonPMBeckAJ. Prisoners in 2004 Washington, DC: Department of Justice (US), Office of Justice Programs, Bureau of Justice Statistics Bulletin; 2005 Report No.: NCJ210677. Also available from: URL: http://www.ojp.usdoj.gov/bjs/pub/pdf/p04.pdf [cited 2006 Jan 18].
30.
New York State Department of Correctional Services. HUB System: profile of inmate population under custody on January 1, 2004. Albany, NY: NYSDOCS; 2005.
Centers for Disease Control and Prevention (US). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep1998; 47(RR-19):1–39.
33.
KleinSJGieryicSMO'ConnellDAHallJYKlopfLC. Availability of HIV prevention services within New York State correctional facilities during 1999-2000: results of a survey. The Prison Journal2002; 82:69–83.
34.
KleinSJO'ConnellDADevoreBSWrightLNBirkheadGS. Building an HIV continuum for inmates: New York State's criminal justice initiative. AIDS Educ Prev2002; 14(5 Suppl B):114–23.
35.
SmithLCWangLWrightLSabinKMGlebatisDSmithPF. Hepatitis C virus (HCV) seroprevalance among incoming inmates in New York State (NYS) 2000–2001. Poster presentation #793 at the Annual Meeting of the Infectious Diseases Society of America; 2002 Oct 24–27; Chicago, IL.
36.
SpauldingACWeinbaumCMLauDTSterlingRSeeffLBMargolisHS. A framework for management of hepatitis C in prisons. Ann Intern Med2006; 144:762–9.
